Abstract 685P
Background
Both fibrinogen and C-reactive protein (CRP) are biomarkers of systemic inflammation, but differ regarding their half-life, underlying pathophysiological triggers, genetic background and cellular as well as molecular effects. The aim of this study was to investigate the fibrinogen/CRP ratio (FCR) as a prognostic blood-based biomarker for survival outcome in patients with pancreatic cancer.
Methods
609 consecutive patients with pancreatic adenocarcinoma (Stage I-III: n = 253 (41.5%), Stage IV: n = 356 (58.5%) from a tri-center cohort study (Austria and Switzerland) had routine measurements of fibrinogen and CRP levels at the time of diagnosis, and were followed until the occurrence of death-from-any-cause. The FCR was defined as the ratio of fibrinogen (in mg/dL) to CRP (in mg/L).
Results
During a median follow-up period of 3.8 years (range: 3 days-8.4 years), 511 (83.9%) patients died (1-, 3-, and 5-year overall survival (OS) probabilities (95%CI): 45.2% (41.1-49.2), 14.0% (11.2-17.2), and 7.4% (5.0-10.4), respectively. Patients with an elevated FCR, defined as an FCR > 75th percentile of the FCR distribution (cut-off: 145.3 units), had a significantly higher 1-year OS than patients ≤ this cut-off (60.2% vs. 40.2%, p
Conclusions
In this large tri-center cohort of patients with pancreatic adenocarcinoma, we observed a strong association between a high FCR and a lower risk of death in patients with metastatic disease but not in patients with localized disease. An elevated FCR at baseline defines a novel clinical subset of patients with metastatic pancreatic cancer who have a remarkable survival advantage.
Clinical trial identification
Legal entity responsible for the study
N/A
Funding
University Graz, Salzburg, Zurich
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract